Antigen-Targeted Antibody-Based Therapies to Be Featured at Engineered Antibodies Conference & Exposition September 18-19 in Philadelphia
PHILADELPHIA, May 15 /PRNewswire/ -- Late breaking advances on antigen-targeted antibody-based therapies, such as Rituxan & Altarex's utilizing monoclonal antibodies as immunotherapeutic agents for the treatment of certain late-stage cancers will be featured on September 18-19 ``Engineered Antibodies Accelerating Drug Discovery & Development'' conference in Philadelphia, announces Strategic Research Institute.
New presentations on program are Millennium's Rapid Antibody Development Systems and Abgenix's XenoMax(TM) Technology, a highly efficient system for generating fully human antibodies. Also featured on program is Altarex's broad technology platform, which evaluates MAbs for their potential to alter antigen processing in treating cancer.
The world antibodies research community will be convening in Philadelphia to attend, speak, and exhibit at the upcoming meeting. The conference, focused on industrial applications in the pharmaceutical industry, features as presenters many of the leading firms, large and small, developing and commercializing this important new therapeutic technology.
The conference is organized into 4 main sections of 5-8 papers each: Post Genomic HTP Antibody R & D, Novel targets & Selection, MAb Generation, and Preclinical/Clinical Progress. These sections are primarily focused on the research, development and commercialization of antibodies. The final section will also discuss the clinical trials of certain antigen based therapeutics.
Presenting companies are Eli Lilly, GlaxoSmithKline, Genentech, Amgen, Wyeth Ayerst, Millennium Pharmaceuticals, IDEC Pharmaceuticals, The Dow Chemical Company, ICOS Corporation, Imclone Systems, Celltech Group, Biosite, Abgenix, Medarex, Crucell, Altarex, EPIcyte, Xenerex-Division of Avanir Pharma, Biovation, Xencor, Harvard Medical School, and Beckman Research Institute-City of Hope. The scope of this conference will be addressed by Centocor.
To request the agenda, please contact Ed Drilon at edrilon@srinstitute.com or at 212.967.0095, x233. Include your fax number, affiliation and mailing address.... |
